Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1987 1
1988 2
1989 3
1990 3
1991 12
1992 6
1993 3
1994 16
1995 6
1996 11
1997 22
1998 13
1999 24
2000 13
2001 14
2002 20
2003 16
2004 19
2005 15
2006 14
2007 21
2008 11
2009 15
2010 20
2011 15
2012 19
2013 22
2014 31
2015 63
2016 77
2017 58
2018 69
2019 89
2020 92
2021 97
2022 77
2023 121
2024 45

Text availability

Article attribute

Article type

Publication date

Search Results

1,034 results

Results by year

Filters applied: . Clear all
Page 1
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Younossi Z, et al. Hepatology. 2019 Jun;69(6):2672-2682. doi: 10.1002/hep.30251. Hepatology. 2019. PMID: 30179269 Free article. Review.
Because of the close association of NAFLD with type 2 diabetes (T2DM) and obesity, the latest models predict that the prevalence of NAFLD and NASH will increase, causing a tremendous clinical and economic burden and poor patient-reported outcomes. Nonetheless, there is no …
Because of the close association of NAFLD with type 2 diabetes (T2DM) and obesity, the latest models predict that the prevalence of NAFLD an …
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. Hepatology. 2023. PMID: 37363821 Free PMC article.
Intermittent fasting-the future treatment in NASH patients?
Minciuna I, Gallage S, Heikenwalder M, Zelber-Sagi S, Dufour JF. Minciuna I, et al. Hepatology. 2023 Oct 1;78(4):1290-1305. doi: 10.1097/HEP.0000000000000330. Epub 2023 Apr 17. Hepatology. 2023. PMID: 37057877 Review.
Intermittent fasting has recently gained more interest in the scientific community as a possible treatment approach for different components of metabolic syndrome. Basic science and clinical studies have shown that apart from inducing body weight loss, improving cardiometa …
Intermittent fasting has recently gained more interest in the scientific community as a possible treatment approach for different components …
The Use of Rifaximin in Patients With Cirrhosis.
Caraceni P, Vargas V, Solà E, Alessandria C, de Wit K, Trebicka J, Angeli P, Mookerjee RP, Durand F, Pose E, Krag A, Bajaj JS, Beuers U, Ginès P; Liverhope Consortium. Caraceni P, et al. Hepatology. 2021 Sep;74(3):1660-1673. doi: 10.1002/hep.31708. Epub 2021 Jun 7. Hepatology. 2021. PMID: 33421158 Free PMC article. Review.
However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacterial infections, is not accepted because evidence by clinical trials is still very weak. The present review deals in the first part w …
However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacte …
Gut microbiome-brain-cirrhosis axis.
Smith ML, Wade JB, Wolstenholme J, Bajaj JS. Smith ML, et al. Hepatology. 2023 Mar 6:10.1097/HEP.0000000000000344. doi: 10.1097/HEP.0000000000000344. Online ahead of print. Hepatology. 2023. PMID: 36866864
The gut microbiome has emerged as a key mechanism affecting gut-liver, gut-brain, and brain-liver communication. Clinical studies and animal models have demonstrated the significant patterns of gut dysbiosis when cirrhosis is present, both with or without concomitant alcoh …
The gut microbiome has emerged as a key mechanism affecting gut-liver, gut-brain, and brain-liver communication. Clinical studies and …
Emerging immunotherapy for HCC: A guide for hepatologists.
Foerster F, Gairing SJ, Ilyas SI, Galle PR. Foerster F, et al. Hepatology. 2022 Jun;75(6):1604-1626. doi: 10.1002/hep.32447. Epub 2022 Apr 7. Hepatology. 2022. PMID: 35253934 Free PMC article. Review.
Herein, we review the rationale, mechanistic basis and supporting preclinical evidence, and available clinical evidence for immunotherapies in HCC as well as ongoing clinical trials of immunotherapy....
Herein, we review the rationale, mechanistic basis and supporting preclinical evidence, and available clinical evidence for immunothe …
Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitis.
Harrington C, Krishnan S, Mack CL, Cravedi P, Assis DN, Levitsky J. Harrington C, et al. Hepatology. 2022 Dec;76(6):1862-1879. doi: 10.1002/hep.32591. Epub 2022 Jun 8. Hepatology. 2022. PMID: 35611859 Free PMC article. Review.
Furthermore, current regimens lead to adverse effects and reduced quality of life, whereas medication titration is imprecise. Biomarkers that can predict the clinical course of disease, identify patients at elevated risk for relapse, and improve monitoring and medication d …
Furthermore, current regimens lead to adverse effects and reduced quality of life, whereas medication titration is imprecise. Biomarkers tha …
Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making.
Dhanasekaran R, Suzuki H, Lemaitre L, Kubota N, Hoshida Y. Dhanasekaran R, et al. Hepatology. 2023 Jun 12:10.1097/HEP.0000000000000513. doi: 10.1097/HEP.0000000000000513. Online ahead of print. Hepatology. 2023. PMID: 37300379
To address this issue, novel clinical trial designs have been proposed and incorporated into recent studies. In this review, we discuss the latest findings in the molecular and immune landscape of HCC for their potential and utility as biomarkers, the framework of evaluati …
To address this issue, novel clinical trial designs have been proposed and incorporated into recent studies. In this review, we discu …
Emerging role of statin therapy in the prevention and management of cirrhosis, portal hypertension, and HCC.
Sharpton SR, Loomba R. Sharpton SR, et al. Hepatology. 2023 Dec 1;78(6):1896-1906. doi: 10.1097/HEP.0000000000000278. Epub 2023 Jan 3. Hepatology. 2023. PMID: 37013380 Review.
We review clinical evidence, derived primarily from retrospective cohort and population-based studies, on the association between statin use and reduction in risk for hepatic decompensation and mortality in persons with established cirrhosis. ...Finally, we highlight ongoi …
We review clinical evidence, derived primarily from retrospective cohort and population-based studies, on the association between sta …
1,034 results